Antibody biopharmaceutical formulations including polymer excipients
US12144862B2 · kind B2 · utility
0Cited by
16References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2023 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | May 23, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Polyacrylamide-based copolymers act as stabilizing excipients in formulations of antibody biopharmaceutical agents without interacting directly with the antibody or altering its pharmacokinetic properties. The polyacrylamide-based copolymers confer a substantial stability benefit to high concentration compositions of a variety of antibodies by precluding adsorption of the antibody to the interfaces of the composition, preventing undesirable aggregation events and maintaining the binding activity of the antibody. Such antibody compositions are useful in methods of administering the composition to a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.